The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
Status:
Completed
Trial end date:
2019-11-19
Target enrollment:
Participant gender:
Summary
The overall objective of this study is to compare the effects of Soliqua, a titratable
combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100
insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of
glucose variability using masked CGM data among people of South Asian origin living in Canada
with type 2 diabetes (T2DM).